21st Nov 2006 07:00
Vernalis PLC21 November 2006 21 November 2006 Vernalis plc to Present at the 18th Annual Piper Jaffray Healthcare Conference in New York on November 30, 2006 WINNERSH, U.K., November 21, 2006 -- Vernalis plc (LSE: VER, Nasdaq: VNLS), aspecialty bio-pharmaceutical and drug development company, today announced thatSimon Sturge, Chief Executive Officer, will present at the 18th Annual PiperJaffray Healthcare Conference to be held November 29, 2006 through December 1,2006 at The Pierre Hotel in New York City. Mr. Sturge is scheduled to present anoverview of the Company's business activities and product pipeline at 4:30 PMEastern time on Thursday, November 30, 2006. Investors may access a live webcast of the presentation at www.vernalis.comunder the Investor Relations tab. The presentation will be accessible for 30days after the event. About Vernalis Vernalis is a speciality bio-pharmaceutical company focused on products marketedto specialist neurologists. The company has two marketed products, Frova(R) andApokyn(R), and a development pipeline focused on neurology and central nervoussystem disorders. The company has seven products in clinical development andcollaborations with leading, global pharmaceutical companies including Novartis,Biogen Idec and Serono. Vernalis has established a US commercial operation topromote Apokyn(R) and co-promote Frova(R) alongside its North American licensingpartner, Endo Pharmaceuticals, progressing the company towards its goal ofbecoming a sustainable, self-funding, R&D-driven, speciality bio-pharmaceuticalcompany. For further information about Vernalis, please visit www.vernalis.com. -- ends --Enquiries:Vernalis plc +44 (0) 118 977 3133Simon Sturge, Chief Executive OfficerTony Weir, Chief Financial OfficerJulia Wilson, Head of Corporate Communications Brunswick Group +44 (0) 20 7404 5959Jon ColesJustine McIlroy Lazar Partners LtdGregory Gin 212-867-1762 Vernalis Forward-Looking Statement This news release may contain forward-looking statements that reflect theCompany's current expectations regarding future events including the clinicaldevelopment and regulatory clearance of the Company's products and includingthat of Frova(R) for menstrual migraine, the Company's ability to find partnersfor the development and commercialisation of its products, the benefits ofre-acquiring Frova(R) in North America and the partnership with Endo on theCompany's liquidity and results of operations, as well as the Company's futurecapital raising activities. Forward-looking statements involve risks anduncertainties. Actual events could differ materially from those projected hereinand depend on a number of factors including the success of the Company'sresearch strategies, the applicability of the discoveries made therein, thesuccessful and timely completion of clinical studies, including with respect toFrova(R) and the Company's other products, the uncertainties related to theregulatory process, the ability of the Company to identify and agree beneficialterms with suitable partners for the commercialisation and/or development ofFrova(R) and other products, as well as the achievement of expected synergiesfrom such transactions, the acceptance of Frova(R) and other products byconsumers and medical professionals, the successful integration of completedmergers and acquisitions and achievement of expected synergies from suchtransactions, and the ability of the Company to identify and consummate suitablestrategic and business combination transactions. This information is provided by RNS The company news service from the London Stock ExchangeRelated Shares:
Vernalis PLC